SUPN Supernus Pharma: Earnings per share for the trailing year

Current sales growth of ADHD medications for adults is generating real revenue for Supernus Pharmaceuticals (SUPN), and the year-over-year EPS trend (trailing 12 months) helps track this momentum, where the indicator reached 265.50. Stable cash flow is based on the lifelong administration of epilepsy medications. Additionally, the company attracts rare specialists by creating a comfortable environment for complex neurobiological research.
Financial and market metric breakdowns for Supernus Pharmaceuticals (SUPN)

This indicator measures the rate of change in earnings per share on a rolling annual basis, allowing for the exclusion of one-time accounting effects to assess the sustainability of capital growth. The high margins of ADHD and CNS disorder treatments, driven by unique drug-release technologies, directly determine the EPS YoY volatility over the last 12 months, reflecting the efficiency of the Supernus Pharmaceuticals (SUPN) business model.